Intronic deletions in the SLC34A3 gene: A cautionary tale for mutation analysis of hereditary hypophosphatemic rickets with hypercalciuria by Ichikawa, Shoji et al.
Intronic deletions in the SLC34A3 gene: A cautionary tale for
mutation analysis of hereditary hypophosphatemic rickets with
hypercalciuria
Shoji Ichikawaa, Shamir Tuchmanb, Leah R. Padgetta, Amie K. Graya, H. Jorge Baluartec,
and Michael J. Econsa,d
aDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, 46202,
U.S.A
bDivision of Pediatric Nephrology, Children's National Medical Center, Washington, District of
Columbia, U.S.A
cDivision of Pediatric Nephrology, The Children's Hospital of Philadelphia, Philadelphia,
Pennsylvania, U.S.A
dDepartment of Medical and Molecular Genetics, Indiana University School of Medicine,
Indianapolis, Indiana, 46202, U.S.A
Abstract
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare metabolic disorder,
characterized by hypophosphatemia, variable degrees of rickets/osteomalacia, and hypercalciuria
secondary to increased serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels. HHRH is caused by
mutations in the SLC34A3 gene, which encodes sodium-phosphate co-transporter type IIc. A 6 ½-
year-old female presented with a history of nephrolithiasis. Her metabolic evaluation revealed
increased 24- hour urine calcium excretion with high serum calcium, low intact parathyroid
hormone (PTH) levels, and elevated 1,25(OH)2D level. In addition, the patient had low to low-
normal serum phosphorus with high urine phosphorus. The patient had normal stature; without
rachitic or boney deformities or a history of fractures. Genetic analysis of SLC34A3 revealed the
patient to be a compound heterozygote for a novel single base pair deletion in exon 12 (c.
1304delG) and 30-base pair deletion in intron 6 (g.1440–1469del). The single-base pair mutation
causes a frameshift, which results in premature stop codon. The intronic deletion is likely caused
by misalignment of the 4-basepair homologous repeats and results in the truncation of an already
small intron to 63 bp, which would impair proper RNA splicing of the intron. This is the fourth
unique intronic deletion identified in patients with HHRH, suggesting the frequent occurrence of
sequence misalignments in SLC34A3 and the importance of screening introns in patients with
HHRH.
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Introduction
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH; OMIM 241530) is a rare
genetic disorder of phosphate homeostasis, which was first described in a large Bedouin
kindred [1]. Similar to other genetic phosphate wasting disorders such as X-linked
hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR),
HHRH is classically characterized by decreased renal phosphate reabsorption,
hypophosphatemia, and rickets/osteomalacia [1, 2]. In addition, individuals with HHRH
often suffer from bone pain, muscle weakness, and growth retardation [1]. However, HHRH
is distinguished from XLH and ADHR by the presence of an appropriately elevated level of
serum 1,25- dihydroxyvitamin D [1,25(OH)2D; calcitriol] concentration, which leads to
hypercalciuria and suppression of parathyroid hormone (PTH) secretion [1, 2]. The attendant
hypercalciuria can lead to the formations of kidney stones and/or the occurrence of
nephrocalcinosis in affected patients. HHRH is caused by mutations occurring in the
SLC34A3 gene, which encodes the sodium-phosphate co-transporter type IIc (NaPi-IIc or
NPT2c) [3, 4]. NaPi-IIc, along with NaPi-IIa encoded by SLC34A1, reabsorb most of
filtered phosphate in the renal proximal tubule, and expression of these co-transporters are
regulated by two phosphaturic hormones – PTH and fibroblast growth factor 23 (FGF23).
Most mutations reported to date are single nucleotide substitutions, leading to changes in
encoded amino acids. However, there have been reports of intronic deletions that affect
intron sizes rather than splice sites [5]. In this study, we performed mutation analysis of the
SLC34A3 gene in a 6 ½-year-old patient presenting with kidney stones and lab/clinic
parameters consistent with HHRH.
Subjects and Methods
Case
Our patient is an 11–1/2 year old female that presented at 6 years of age with gross
hematuria, right flank pain, nausea, dysuria, and urinary urgency. She was diagnosed with a
right lower-pole renal calculus via abdominal CT which otherwise revealed normal size and
appearance of both kidneys. The patient was well developed without rachitic or boney
deformities. Height was at the 20th percentile. The patient had no history of fractures. There
was neither a family history of rickets nor kidney stone disease. As shown in Table 1, her
initial metabolic evaluation revealed a 24-hour urine calcium excretion of 17.8 mg/kg/day
(normal < 4 mg/kg/day) with a serum calcium level of 9.6 mg/dL and intact PTH of 12.6 pg/
mL. The patient had a serum phosphorus of 3.0 mg/dL (normal 3.7 – 5.6), 25-
hydroxyvitamin D [25(OH)D] level was 42.4 ng/mL with a 1,25(OH)2D of 127 pg/mL
(normal 15 – 90). FGF23 level was 56 pg/mL (normal, 29.7 ± 20.7) [6]. The patient had
normal renal function with an estimated GFR of 95 ml/min/1.73m2. Her urinalysis was
unremarkable without glucosuria or proteinuria. Her urine beta-2 microglobulin excretion
was normal (34 μg/gram creatinine). Repeat labs revealed serum phosphorus of 4.0 mg/dL
with a low tubular threshold for phosphate reabsorption (TmP/GFR) of 3.75 mg/dL and
inappropriately high phosphorus excretion of 105 mg/kg/day. A chest x-ray and erythrocyte
sedimentation rate were both normal. A renal ultrasound showed bilateral nephrocalcinosis.
Her biologic parent’s urine calcium to creatinine ratios were in the normal range. The patient
underwent dual x-ray absorptiometry scanning which revealed an L-spine z-score of −1.9.
The patient was supplemented with 2 mmol/kg/day of oral phosphorus. Within a month of
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treatment, the urine calcium to creatinine ratio was reduced to 0.08 despite persistent
elevations in 1,25(OH)2D. An MRI of the lower extremities did not show rickets. She did
pass a 6 mm stone when she first presented in 2007, and in spite of generous fluid intake and
phosphorus supplementation, she had another episode of renal colic at age 9 years,
secondary to another passing kidney stone. A renal ultrasound at that time showed a 7 mm
stone in the right UVJ with hydronephrosis and pelviectasis. At her follow up visit in August
2011, a timed urine collection showed a high urinary calcium (10.7 mg/Kg/day), bone age
films did not show rickets and her biochemical profile revealed a serum creatinine of 0.7
mg/dl (eGFR 107 ml/min.1.73 m2), serum calcium of 10.8 mg/dl (normal range 8.6–10.2),
serum phosphorus 4.0 (normal range 4.1–5.4), intact PTH 6 pg/ml (normal range 12–65),
and 1,25(OH)2D of 78 pg/ml. Her treatment consisted of phosphorus supplementation (K-
Phos neutral) 2,750 mg/day in three divided doses.
The study was approved by the Institutional Review Board of Indiana University-Purdue
University Indianapolis. Written informed consent was obtained from the patient’s legal
guardians prior to participation in the study.
Mutation Analysis—Genomic DNA was extracted from blood obtained from the patient.
All 13 exons (one non-coding and 12 coding), as well as adjacent intronic sequences, were
amplified in eight fragments using Multiplex PCR Kit (QIAGEN Inc., Valencia, CA).
Primer sequences and PCR conditions are available upon request. PCR products were
electrophoresed in a 2% agarose gel and purified using DNA Gel Extraction Kit (QIAGEN).
Approximately 100 ng of PCR products were directly sequenced from forward and/or
reverse PCR primer, using Big-Dye Terminator Cycle Sequencing Kit and the ABI PRISM
3100 Genetic Analyzer (Applied Biosystems).
Sequence variations identified by DNA sequencing were tested in race-matched control
DNA samples. Single nucleotide deletion in exon 12 was analyzed by PCR-RFLP analysis.
Genomic DNA fragments were amplified by PCR (forward: 5’-
ACGTTGGATGTGCTGGCTGCCCTGGTCA-3’ and reverse: 5’-
ACGTTGGATGGTGGGACTCGGCCTTTGCAG-3’). The 10-bp tails (italicized) were
added to each primer to improve separation between normal and mutant alleles during
agarose gel electrophoresis. The mismatch nucleotide (underlined) was introduced in the
forward primer to create BstEII (New England Biolabs, Beverly, MA) restriction site only in
the mutant allele. The digested PCR products were electrophoresed in an agarose gel and
visualized under the UV light. Deletion in intron 6 was tested by using the same PCR
primers originally used for sequencing the patient, and the PCR products were directly
analyzed by agarose gel electrophoresis.
Results
Genetic analysis of the SLC34A3 gene revealed that the patient is a compound heterozygote
for a single base pair deletion in exon 12 (c.1304delG) and 30-basepair deletion in intron 6
(g.1440–1469del) (Figure 1A-B). While the intronic deletion was not found in over 180
unrelated healthy white controls, the deletion in exon 12 was found in one of 200 controls.
The c.1304delG mutation results in a shift in the open reading frame, leading to the
premature termination of the encoded NaPi-IIc protein – 599 amino acids to 479 amino
acids. The other deletion is located in intron 6 and does not remove any apparent cis-acting
elements, including conserved donor and acceptor splice sites. Instead, it only reduces the
intron size from 93 base pairs to 63. The sequence analysis of the deleted region showed the
presence of four base pair direct repeats (GGGC) in the middle of intron 6 – g.1436–1439
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and g.1466–1469 (Figure 1C). These repeats likely promote misalignment during meiosis,
leading to deletion of one of the repeats and the sequence flanked by the repeats.
Discussion
In the present study, we describe an 11 1/2-year-old girl with increased urinary excretion of
calcium and phosphorus and recurrent nephrolithiasis. Despite persistent hypophosphatemia
and low bone mineral density, the patient did not have any apparent bone deformities or
rachitic changes. However, the clinical phenotype of HHRH can be quite variable even in
the same family. Two siblings in the previously described HHRH family carried the
identical mutations; however, only one developed bone abnormalities without kidney stones
and the other had no bone defects, but had recurrent nephrolithiasis [5]. We cannot rule out
the possibility that the patient described in this study may develop bone abnormalities in the
future.
The patient carries compound heterozygous mutations in the SLC34A3 gene. The c.
1304delG mutation is a novel mutation that causes frameshift in the reading frame. The
other mutation is a deletion in intron 6, which was also recently found in an unrelated family
with HHRH [7]. As in our previous study of similar intronic deletions in this gene [5], this
deletion does not remove any apparent cis-acting elements, but only reduces intron size to
63 bp – below the minimally required size of approximately 87–92 bp in humans [8, 9].
Therefore, the deletion likely prevents proper RNA processing, leading to retention of the
truncated intron 6.
This is the fourth unique intronic deletion identified in HHRH kindreds: 30-bp deletion in
intron 6 (g.1440–1469del) (this study, [7]), 101-bp deletion in intron 9 (g.2259_2359del) [3,
5, 10], 85-bp deletion in intron 10 (g.2615_2699del) [5], and 26-bp deletion in intron 12 (g.
4225_50del) [11]. The deletions found in introns 6, 9, and 10 all appear to affect the
minimal intron size required for proper splicing, whereas the deletion in intron 12 likely
removes cis-acting elements at acceptor splice site [11]. Frequent intronic deletions in the
small number of reported HHRH cases are intriguing and are also important from the
genetic analysis perspective. All four intronic mutations described to date involve
homologous sequence repeats (Figure 2), suggesting the same molecular mechanism for the
deletion. These repeats likely facilitate misalignment during meiosis and remove the internal
sequences between the repeats (along with one of the repeats). Furthermore, the SLC34A3
gene (variant 1, NM_001177316.1) is a relatively small gene (5,798 bp), which harbors 13
exons and has high GC content of 66.9%. Since GC content is inversely related to intron
size [9], it is not surprising that many of the SLC34A3 introns are significantly smaller than
average intron size – mean 3,749 bp, median 1,334 bp [12] (Table 2). However, as we
postulated previously [5], the existence of homologous repeats in or near these small introns
likely make the SLC34A3 gene particularly vulnerable to unequal crossing over events
affecting intron sizes. Since HHRH is an autosomal recessive disease, biallelic mutations are
required for full-scale disease manifestations. However, clinical phenotypes are sometimes
seen in carriers of single SLC34A3 mutations [3–5, 13, 14], some of which could be
explained by the inability to find second mutations. In heterozygous individuals, deletions
could be easily missed if PCR primers were designed within the deleted sequences because
one normal allele would allow amplification and mask the presence of the deletion. In
addition, routine genetic testing only screens exons and adjacent intron sequences, and most
intronic sequences go unscreened. Thus, screening of SLC34A3 introns should be considered
part of genetic analysis for HHRH, particularly when only one mutation is found in the
affected patients. In this regard, we screen 13 SLC34A3 exons in eight fragments, which
cover most of the small introns [5]. Alternatively, PCR amplification and sequencing of the
entire gene in four overlapping fragments – the approach used by Bergwitz and colleagues
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[3] – ensures screening of all exons and introns in this gene. In conclusion, we identified two
SLC34A3 mutations in a patient with HHRH. One of the mutations was a disease-causing
deletion in a short intron, likely leading to retention of the truncated intron. The frequent
deletion events in SLC34A3 suggest that the gene is particularly susceptible to unequal
crossovers due to the existence of intragenic homologous sequences in or near small introns.
More importantly, prevalent intronic deletions indicate the critical importance of including
introns as a part of genetic analysis for HHRH.
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Highlights
• Compound heterozygous mutations, c.1304delG and g.1440–1469del, were
identified in a patient with HHRH.
• The deletion in intron 6 (g.1440–1469del) is the fourth intronic deletion found
in the SLC34A3 gene.
• The intronic deletion is likely mediated by sequence misalignments of
homologous repeats and affects minimal intron size required for splicing.
• Frequent deletions in the SLC34A3 introns suggest the importance of screening
introns in genetic analysis of HHRH.
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Figure 1.
SLC34A3 mutations in the HHRH patient. A. Deletion in intron 6. Agarose gel
electrophoresis shows three distinct PCR products from the patient. DNA sequencing
revealed that top, middle and bottom products represent wild-type/mutant heteroduplex,
wild-type, and mutant, respectively. WT, wild type. B. Electropherogram of exon 12. The
arrow denotes a deletion of nucleotide “G”. C. Sequence analysis near the intron 6 deletion.
The deletion (underline) likely involves four base pair repeats (in blue), which are separated
by 26 bp. These short direct repeats are predicted to promote sequence misalignment during
meiosis, leading to deletion of one of the repeats along with internal sequence between the
repeats. Upper case, exon; lower case, intron.
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Figure 2.
Homologous sequences involved in intronic deletions in the SLC34A3 gene. Direct repeats
of homologous sequences (gray highlights) likely misalign during meiosis, resulting in
deletions of one of the repeats and the sequence flanked by the repeats. Uppercase and lower
cases denote exonic and intronic sequences, respectively. Underlines denote deleted
sequences. The most 3’ repeats are arbitrarily assigned to be deleted.
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Table 2
Characteristics of introns in the SLC34A3 gene
Intron Length (bp)1 GC
(%)1
1 725 64.7
2 284 65.5
3 413 67.6
4 80 71.3
5 76 76.3
6 93 73.1
7 228 74.1
8 140 67.1
9 167 76.0
10 139 70.5
11 74 70.4
12 1220 65.6
1
Based on transcript variant 1 (RefSeq NM_001177316.1)
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